Zevra Therapeutics, Inc. (ZVRA) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-449.8%

-$35.33

vs $10.10 price

Levered DCF

-$40.04

After debt service

Piotroski score

6 / 9

Average

Altman Z-score

4.53

Safe zone

Rating

A-

Overall 4 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	6.4×	-3.66×	-5.04×	-5.88×	-4.13×	-3.49×	-0.46×	-0.57×
P/B	3.2×	9.72×	3.75×	2.11×	2.04×	-0.67×	-0.15×	-0.48×
P/S	4.65×	16.34×	8.46×	15.58×	9.05×	3.36×	0.88×	0×
EV / EBITDA	5.03×	-5.4×	-5.35×	-4.37×	-18.83×	-20.42×	-4.94×	-1.77×
Gross margin	84.5%	68.6%	89.3%	97.8%	92.8%	90.2%	77.1%	0.0%
Operating margin	-4.0%	-368.5%	-180.6%	-418.9%	27.0%	-42.2%	-158.4%	0.0%
Net margin	78.2%	-446.9%	-167.7%	-263.5%	-29.9%	-96.0%	-191.0%	0.0%
Current ratio	5.68×	2.53×	1.18×	7.72×	27.2×	1.11×	1.28×	1.98×
Debt / equity	0.41×	1.52×	0.71×	0.25×	0.01×	-1.06×	-1.07×	-1.23×
Interest coverage	-0.53×	-11.84×	-33.05×	-127.06×	20.56×	-0.79×	-3.12×	-7.89×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	53.8%	-266.0%	-74.4%	-35.6%	-6.7%	19.2%	32.9%	84.8%
Return on invested capital	-1.7%	-60.2%	-36.2%	-39.2%	6.0%	-122.6%	-379.1%	-305.0%
Return on assets	29.2%	-59.2%	-26.7%	-23.2%	-6.4%	-113.8%	-233.4%	-211.1%
Free cash flow yield	-0.5%	-18.1%	-14.6%	-11.9%	4.0%	-4.4%	-211.4%	-169.9%
Earnings yield	16.8%	-27.4%	-19.8%	-16.9%	-3.3%	-28.6%	-218.2%	-176.9%
Enterprise value	$496.4M	$412.2M	$232.9M	$111.6M	$148.5M	$110.9M	$87.6M	$95.6M
Net debt / EBITDA	0.01×	-0.35×	-0.02×	1.83×	14.04×	-12.21×	-4.31×	-1.18×
Cash conversion cycle (days)	63	-384	1,482	-5,639	-72	-258	-88	-4,185